knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 22:58:49 - browse：4412

Microsoft's head of research Peter Lee speaking at STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to experiment with it before there is wider consensus on how to navigate its biases and other pitfalls, Microsoft’s head of research Peter Lee said Thursday at STAT’s Breakthrough Summit.

About a month after OpenAI — Microsoft has a significant financial stake in the company — launched its chatbot in 2022 on November 30, which happened to be Lee’s birthday, he got a note from a doctor friend who said he’d used it so his receptionist could file after-visit summaries for patients. While Lee and a handful of other doctors at Microsoft had been impressed with the GPT-4’s capabilities, they knew it had weaknesses.

“The emotions were really mixed. I mean we were thrilled,” he said, but then “just within minutes there’s a feeling of dread. We had already come to the realization that GPT-4 would be prone to issues, issues of bias, hallucination, mathematical and logical errors,” he said. “And so, there’s an immediate question: ‘Should we allow this to happen?’”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections
Next article： J&J reports mixed data on next

WSS

For BCIs, commercial hurdles may be bigger than scientific ones

Biden calls for immediate release of Niger's president amid apparent coup

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Decentralized clinical trials need collaboration to achieve wider use

'Ancient DNA,' 23andMe reveal African American ancestries

Asahi Kasei to buy Calliditas, picking up kidney disease drug

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

ER docs worry over extreme heat as a 'mass casualty event'

Apple is now the first public company to be valued at $3 trillion

Unmasking the 'centricity' illusion in clinical trials

Anesthesiologist group: stop taking Ozempic before surgery

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Dobbs anniversary: the lost opportunity of abortion as health care

Humana, CVS hope to turn members into patients at clinics

How one medical school became remarkably diverse

ProMED, early warning system on disease outbreaks, in peril

hotspot

ER docs worry over extreme heat as a 'mass casualty event'

Verily hires former Apple Health leader as chief scientific officer

TytoCare raises $49 million to build out AI

The drug industry sees a key ally in the Senate prevail

The Bio Revolution is changing business and society

'Ancient DNA,' 23andMe reveal African American ancestries

hotspot

focus

knowledge

entertainment